trastuzumab emtansine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 4990 1018448-65-1

Description:

MoleculeDescription

Synonyms:

  • trastuzumab-DM1 conjugate
  • trastuzumab emtansine
  • ado-trastuzumab emtansine
  • kadcyla
  • PRO132365
  • trastuzumab-MCC-DM1
  • T-DM1
  • huN901-DM1
Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.
  • Molecular weight:
  • Formula: (C47H62ClN4O14S)3-4
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 15, 2013 EMA
Feb. 22, 2013 FDA GENENTECH
Sept. 20, 2013 PMDA Chugai Pharmaceutical Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 684.47 22.40 451 20298 122307 63345966
Metastases to central nervous system 539.48 22.40 191 20558 12914 63455359
Neuropathy peripheral 316.05 22.40 276 20473 113391 63354882
Ejection fraction decreased 305.19 22.40 148 20601 22184 63446089
Platelet count decreased 295.10 22.40 268 20481 115854 63352419
Thrombocytopenia 292.07 22.40 300 20449 150857 63317416
Epistaxis 186.79 22.40 169 20580 72556 63395717
Metastases to lymph nodes 178.06 22.40 75 20674 8083 63460190
Metastases to lung 160.70 22.40 80 20669 12670 63455603
Nodular regenerative hyperplasia 131.43 22.40 31 20718 475 63467798
Palmar-plantar erythrodysaesthesia syndrome 131.22 22.40 86 20663 22929 63445344
Radiation necrosis 127.52 22.40 29 20720 375 63467898
Malignant neoplasm progression 126.78 22.40 145 20604 81976 63386297
Metastases to bone 118.50 22.40 78 20671 20941 63447332
Myelosuppression 105.41 22.40 76 20673 23627 63444646
Metastases to skin 103.08 22.40 33 20716 1630 63466643
Cardiotoxicity 100.60 22.40 51 20698 8387 63459886
Portal hypertension 93.09 22.40 38 20711 3781 63464492
Neoplasm progression 90.20 22.40 83 20666 36345 63431928
Spider naevus 86.44 22.40 18 20731 149 63468124
Joint swelling 84.04 22.40 6 20743 327660 63140613
Blood lactate dehydrogenase increased 82.53 22.40 65 20684 23051 63445222
Metastases to liver 81.25 22.40 65 20684 23574 63444699
Aspartate aminotransferase increased 79.47 22.40 121 20628 90156 63378117
Excessive eye blinking 73.62 22.40 24 20725 1256 63467017
Pneumonitis 73.45 22.40 73 20676 35149 63433124
Metastasis 72.62 22.40 35 20714 5162 63463111
Blood uric acid decreased 71.35 22.40 21 20728 780 63467493
Left ventricular dysfunction 71.26 22.40 46 20703 11942 63456331
Drug hypersensitivity 70.94 22.40 9 20740 310678 63157595
Rheumatoid arthritis 70.15 22.40 3 20746 253816 63214457
Polyneuropathy 69.98 22.40 49 20700 14540 63453733
Alanine aminotransferase increased 69.58 22.40 123 20626 103647 63364626
Breast cancer recurrent 69.15 22.40 32 20717 4309 63463964
Breast cancer metastatic 66.28 22.40 44 20705 11974 63456299
Product dose omission issue 63.99 22.40 3 20746 234310 63233963
Axillary pain 63.35 22.40 24 20725 1959 63466314
Recurrent cancer 63.30 22.40 24 20725 1963 63466310
Eosinophil percentage increased 62.06 22.40 20 20729 1009 63467264
Vascular device infection 61.36 22.40 35 20714 7277 63460996
Hyperchlorhydria 57.76 22.40 22 20727 1822 63466451
Blood alkaline phosphatase increased 56.57 22.40 70 20679 42897 63425376
Abdominal discomfort 55.33 22.40 18 20731 320867 63147406
Constipation 54.98 22.40 180 20569 224763 63243510
Telangiectasia 54.60 22.40 18 20731 976 63467297
Pleural effusion 54.30 22.40 104 20645 93106 63375167
Hepatotoxicity 53.09 22.40 63 20686 36978 63431295
Systemic lupus erythematosus 53.03 22.40 4 20745 208914 63259359
Mucosal inflammation 51.69 22.40 70 20679 46858 63421415
Arthropathy 50.76 22.40 8 20741 234784 63233489
Blood creatinine decreased 50.48 22.40 28 20721 5517 63462756
Treatment failure 49.98 22.40 4 20745 199039 63269234
Diarrhoea 49.83 22.40 401 20348 714965 62753308
Drug interaction 49.10 22.40 8 20741 229123 63239150
Gamma-glutamyltransferase increased 48.96 22.40 58 20691 33973 63434300
Interstitial lung disease 48.93 22.40 79 20670 61829 63406444
Metastases to spine 48.81 22.40 23 20726 3226 63465047
Hypertransaminasaemia 48.50 22.40 29 20720 6580 63461693
Gingival bleeding 48.42 22.40 37 20712 12550 63455723
Non-cirrhotic portal hypertension 48.40 22.40 12 20737 229 63468044
Breast neoplasm 48.17 22.40 18 20731 1414 63466859
Peripheral sensory neuropathy 47.79 22.40 30 20719 7421 63460852
Dyschezia 46.44 22.40 20 20729 2274 63465999
Radiation pneumonitis 46.41 22.40 18 20731 1565 63466708
Asthenopia 46.08 22.40 20 20729 2317 63465956
Nail dystrophy 45.93 22.40 16 20733 1027 63467246
Ejection fraction 45.52 22.40 20 20729 2386 63465887
Vessel puncture site bruise 45.42 22.40 13 20736 437 63467836
Blood bilirubin increased 44.91 22.40 58 20691 37082 63431191
Breast disorder 44.55 22.40 20 20729 2510 63465763
Condition aggravated 44.06 22.40 40 20709 402177 63066096
Hepatic cirrhosis 43.86 22.40 47 20702 24687 63443586
Performance status decreased 43.17 22.40 22 20727 3656 63464617
Swelling 43.15 22.40 18 20731 275360 63192913
Tumour marker increased 42.52 22.40 24 20725 4891 63463382
Hypokalaemia 42.13 22.40 100 20649 103704 63364569
Haematotoxicity 41.52 22.40 30 20719 9346 63458927
Nausea 41.33 22.40 443 20306 854028 62614245
Neutropenia 40.90 22.40 138 20611 174867 63293406
Lymphangiosis carcinomatosa 40.84 22.40 16 20733 1429 63466844
Dry skin 38.83 22.40 68 20681 56819 63411454
Hypothalamo-pituitary disorder 38.82 22.40 13 20736 740 63467533
Folate deficiency 38.66 22.40 18 20731 2457 63465816
Sinusitis 38.54 22.40 13 20736 226640 63241633
Death 38.44 22.40 231 20518 374150 63094123
Brain oedema 38.38 22.40 34 20715 14161 63454112
Lacrimation increased 37.99 22.40 40 20709 20591 63447682
Discomfort 37.80 22.40 5 20744 167369 63300904
Carcinoembryonic antigen increased 37.75 22.40 16 20733 1749 63466524
Vulvovaginal candidiasis 37.29 22.40 19 20730 3156 63465117
Hiccups 37.27 22.40 17 20732 2214 63466059
Drug intolerance 37.12 22.40 28 20721 308633 63159640
Hyperbilirubinaemia 36.52 22.40 30 20719 11284 63456989
Pituitary tumour 35.89 22.40 13 20736 935 63467338
Eastern Cooperative Oncology Group performance status worsened 35.85 22.40 14 20735 1240 63467033
Cellulitis 35.49 22.40 81 20668 81877 63386396
Arteriovenous malformation 34.75 22.40 14 20735 1346 63466927
Injection site extravasation 34.03 22.40 26 20723 8815 63459458
Ascites 33.58 22.40 53 20696 40675 63427598
Hydrocephalus 33.14 22.40 21 20728 5279 63462994
Splenomegaly 32.74 22.40 28 20721 11129 63457144
Gastrointestinal toxicity 32.54 22.40 24 20725 7717 63460556
Decreased appetite 32.49 22.40 165 20584 250887 63217386
Nail infection 32.28 22.40 16 20733 2507 63465766
Bone marrow infiltration 32.08 22.40 11 20738 673 63467600
Pericarditis 32.05 22.40 3 20746 131576 63336697
Lymphoedema 31.60 22.40 28 20721 11664 63456609
Hepatic function abnormal 31.55 22.40 49 20700 37093 63431180
Musculoskeletal stiffness 30.67 22.40 11 20738 184607 63283666
Therapeutic product effect decreased 29.65 22.40 13 20736 193174 63275099
Tumour haemorrhage 29.06 22.40 13 20736 1618 63466655
Varices oesophageal 28.94 22.40 16 20733 3132 63465141
Metastases to meninges 28.91 22.40 15 20734 2587 63465686
Hand dermatitis 28.79 22.40 8 20741 241 63468032
Biliary sepsis 28.77 22.40 11 20738 920 63467353
Intracranial pressure increased 28.49 22.40 19 20730 5208 63463065
Pulmonary mass 28.43 22.40 36 20713 22560 63445713
Transaminases increased 27.51 22.40 42 20707 31325 63436948
Arthritis 27.31 22.40 3 20746 115918 63352355
Extravasation 27.29 22.40 14 20735 2358 63465915
Central nervous system infection 27.26 22.40 10 20739 746 63467527
Left ventricular dilatation 27.23 22.40 9 20740 492 63467781
Cough 26.50 22.40 175 20574 292568 63175705
Maternal exposure during pregnancy 26.39 22.40 20 20729 220042 63248231
Poor peripheral circulation 26.34 22.40 16 20733 3733 63464540
Stomatitis 26.12 22.40 102 20647 138623 63329650
Product use in unapproved indication 26.02 22.40 13 20736 179067 63289206
Drug ineffective 26.00 22.40 218 20531 1044547 62423726
Device related infection 25.91 22.40 35 20714 23357 63444916
Paravenous drug administration 25.87 22.40 4 20745 3 63468270
Breast pain 25.65 22.40 22 20727 8776 63459497
Pleural neoplasm 25.64 22.40 8 20741 363 63467910
Therapeutic product effect incomplete 25.40 22.40 5 20744 125051 63343222
Intracranial tumour haemorrhage 25.38 22.40 7 20742 205 63468068
Anal erythema 25.38 22.40 7 20742 205 63468068
Skin toxicity 25.36 22.40 17 20732 4697 63463576
Seizure 25.36 22.40 98 20651 132536 63335737
Wound 25.03 22.40 11 20738 163252 63305021
Nail bed tenderness 24.87 22.40 8 20741 401 63467872
Mean cell haemoglobin concentration decreased 24.32 22.40 15 20734 3597 63464676
Toxicity to various agents 24.28 22.40 27 20722 247223 63221050
Asthma 24.09 22.40 6 20743 127555 63340718
Blood phosphorus decreased 23.82 22.40 16 20733 4437 63463836
Catheter site haemorrhage 23.47 22.40 14 20735 3161 63465112
Lymphocyte count decreased 23.06 22.40 38 20711 30219 63438054
Rectal haemorrhage 22.95 22.40 50 20699 48980 63419293
Fall 22.77 22.40 60 20689 392274 63075999
Scintillating scotoma 22.66 22.40 6 20743 150 63468123
Nail discolouration 22.64 22.40 13 20736 2737 63465536
Skin fissures 22.62 22.40 23 20726 11365 63456908
Bone pain 22.55 22.40 53 20696 54588 63413685
Odynophagia 22.40 22.40 19 20730 7467 63460806

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paranasal sinus discomfort 59.16 49.68 10 408 830 34955683

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 365.72 23.17 315 17723 184047 79542303
Metastases to central nervous system 340.27 23.17 131 17907 16244 79710106
Neuropathy peripheral 245.14 23.17 224 17814 141081 79585269
Ejection fraction decreased 226.86 23.17 124 17914 34453 79691897
Platelet count decreased 195.22 23.17 230 17808 194434 79531916
Metastases to lymph nodes 156.54 23.17 66 17972 10331 79716019
Thrombocytopenia 142.58 23.17 232 17806 265027 79461323
Metastases to lung 135.56 23.17 71 17967 18092 79708258
Epistaxis 117.02 23.17 135 17903 111380 79614970
Metastases to bone 108.33 23.17 68 17970 24359 79701991
Metastases to skin 96.13 23.17 29 18009 1710 79724640
Malignant neoplasm progression 95.73 23.17 135 17903 135855 79590495
Palmar-plantar erythrodysaesthesia syndrome 91.77 23.17 69 17969 33065 79693285
Myelosuppression 83.97 23.17 71 17967 40225 79686125
Constipation 72.55 23.17 182 17856 282868 79443482
Blood lactate dehydrogenase increased 71.49 23.17 64 17974 39106 79687244
Nodular regenerative hyperplasia 68.00 23.17 21 18017 1340 79725010
Cardiotoxicity 66.97 23.17 39 17999 12200 79714150
Left ventricular dysfunction 66.61 23.17 46 17992 19315 79707035
Drug interaction 66.42 23.17 8 18030 415175 79311175
Axillary pain 66.21 23.17 23 18015 2126 79724224
Metastases to liver 65.47 23.17 53 17985 28261 79698089
Neoplasm progression 65.28 23.17 69 17969 51613 79674737
Breast cancer metastatic 65.24 23.17 34 18004 8568 79717782
Blood uric acid decreased 64.88 23.17 20 18018 1268 79725082
Spider naevus 63.69 23.17 13 18025 145 79726205
Excessive eye blinking 63.39 23.17 21 18017 1680 79724670
Polyneuropathy 61.83 23.17 48 17990 24103 79702247
Aspartate aminotransferase increased 60.84 23.17 111 17927 138530 79587820
Eosinophil percentage increased 57.61 23.17 19 18019 1499 79724851
Nausea 53.91 23.17 385 17653 956811 78769539
Ejection fraction 53.78 23.17 20 18018 2249 79724101
Lymphoedema 53.63 23.17 34 18004 12379 79713971
Asthenopia 52.47 23.17 20 18018 2407 79723943
Diarrhoea 52.40 23.17 359 17679 880130 78846220
Nail dystrophy 52.17 23.17 16 18022 997 79725353
Alanine aminotransferase increased 51.92 23.17 114 17924 162456 79563894
Hyperchlorhydria 51.76 23.17 19 18019 2060 79724290
Radiation necrosis 50.30 23.17 13 18025 432 79725918
Joint swelling 50.23 23.17 4 18034 288642 79437708
Blood alkaline phosphatase increased 48.95 23.17 66 17972 63598 79662752
Vessel puncture site bruise 48.49 23.17 13 18025 499 79725851
Blood creatinine decreased 48.36 23.17 27 18011 7798 79718552
Vulvovaginal candidiasis 48.25 23.17 19 18019 2495 79723855
Tumour marker increased 47.74 23.17 22 18016 4250 79722100
Vascular device infection 46.54 23.17 29 18009 10247 79716103
Gamma-glutamyltransferase increased 45.61 23.17 59 17979 54621 79671729
Breast disorder 44.45 23.17 17 18021 2064 79724286
Recurrent cancer 43.57 23.17 18 18020 2675 79723675
Telangiectasia 42.69 23.17 15 18023 1434 79724916
Product dose omission issue 41.51 23.17 4 18034 247533 79478817
Toxicity to various agents 41.24 23.17 22 18016 421518 79304832
Drug hypersensitivity 40.56 23.17 9 18029 298907 79427443
Lymphangiosis carcinomatosa 40.36 23.17 16 18022 2138 79724212
Carcinoembryonic antigen increased 39.97 23.17 16 18022 2193 79724157
Portal hypertension 39.82 23.17 23 18015 7085 79719265
Non-cirrhotic portal hypertension 39.75 23.17 11 18027 476 79725874
Lacrimation increased 39.58 23.17 36 18002 22441 79703909
Hepatotoxicity 39.11 23.17 53 17985 51299 79675051
Gingival bleeding 38.75 23.17 31 18007 16245 79710105
Nail infection 38.69 23.17 16 18022 2383 79723967
Dry skin 38.48 23.17 61 17977 67934 79658416
Injection site extravasation 38.11 23.17 25 18013 9644 79716706
Nasopharyngitis 37.99 23.17 135 17903 253746 79472604
Hypertransaminasaemia 37.91 23.17 27 18011 11897 79714453
Hypothalamo-pituitary disorder 37.64 23.17 13 18025 1181 79725169
Hepatopulmonary syndrome 37.60 23.17 7 18031 46 79726304
Performance status decreased 37.52 23.17 21 18017 6092 79720258
Pituitary tumour 37.34 23.17 13 18025 1209 79725141
Gastrointestinal toxicity 37.01 23.17 23 18015 8086 79718264
Folate deficiency 36.60 23.17 17 18021 3343 79723007
Rheumatoid arthritis 35.95 23.17 3 18035 208467 79517883
Peripheral sensory neuropathy 35.76 23.17 27 18011 13006 79713344
Metastases to spine 35.41 23.17 18 18020 4306 79722044
Urinary tract infection 35.27 23.17 139 17899 274373 79451977
Hypokalaemia 35.14 23.17 91 17947 143949 79582401
Bone marrow infiltration 35.12 23.17 11 18027 735 79725615
Fatigue 34.11 23.17 340 17698 929387 78796963
Eastern Cooperative Oncology Group performance status worsened 34.08 23.17 14 18024 2051 79724299
Radiation pneumonitis 34.05 23.17 17 18021 3916 79722434
Cellulitis 33.14 23.17 75 17963 108985 79617365
Metastasis 32.64 23.17 20 18018 6860 79719490
Pneumonitis 32.26 23.17 53 17985 60807 79665543
Condition aggravated 31.84 23.17 40 17998 501084 79225266
Drug ineffective 31.49 23.17 132 17906 1080781 78645569
Cough 30.90 23.17 164 17874 366625 79359725
Acute kidney injury 30.42 23.17 44 17994 519360 79206990
Bone pain 30.16 23.17 49 17989 55693 79670657
Pulmonary mass 30.15 23.17 35 18003 28999 79697351
Weight decreased 30.05 23.17 159 17879 355039 79371311
Mucosal inflammation 30.00 23.17 58 17980 75522 79650828
Pleural effusion 29.68 23.17 86 17952 145176 79581174
Decreased appetite 29.46 23.17 154 17884 342264 79384086
Interstitial lung disease 29.40 23.17 73 17965 112527 79613823
Arteriovenous malformation 29.27 23.17 12 18026 1749 79724601
Poor peripheral circulation 29.20 23.17 15 18023 3668 79722682
Nail discolouration 28.92 23.17 14 18024 3017 79723333
Pleural neoplasm 28.61 23.17 8 18030 360 79725990
Hand dermatitis 28.25 23.17 8 18030 377 79725973
Hydrocephalus 27.94 23.17 20 18018 8880 79717470
Treatment failure 27.94 23.17 3 18035 170483 79555867
Seizure 27.87 23.17 100 17938 188734 79537616
Nail bed tenderness 27.68 23.17 8 18030 406 79725944
Breast pain 26.93 23.17 19 18019 8246 79718104
Biliary sepsis 26.81 23.17 11 18027 1606 79724744
Atrial fibrillation 26.75 23.17 6 18032 197880 79528470
Metastases to meninges 26.64 23.17 14 18024 3587 79722763
Breast cancer recurrent 26.16 23.17 13 18025 2964 79723386
Mean cell haemoglobin concentration decreased 26.14 23.17 15 18023 4564 79721786
Infusion related reaction 25.94 23.17 112 17926 230125 79496225
Dental fistula 25.70 23.17 8 18030 524 79725826
Central nervous system infection 25.00 23.17 10 18028 1367 79724983
Tumour haemorrhage 24.79 23.17 14 18024 4130 79722220
Stomatitis 24.51 23.17 81 17957 146676 79579674
Hormone receptor positive breast cancer 24.13 23.17 7 18031 360 79725990
Myocardial infarction 24.06 23.17 6 18032 184123 79542227
Spinal pain 23.92 23.17 23 18015 15369 79710981
Renal failure 23.60 23.17 8 18030 200960 79525390
Nasal dryness 23.54 23.17 14 18024 4549 79721801
Left ventricular dilatation 23.54 23.17 9 18029 1092 79725258
Vulvovaginal pain 23.48 23.17 11 18027 2204 79724146
Conjunctivitis 23.42 23.17 29 18009 25686 79700664
Blood phosphorus decreased 23.30 23.17 16 18022 6652 79719698

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FD03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
MeSH PA D050256 Antimitotic Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D018796 Immunoconjugates
MeSH PA D007155 Immunologic Factors
MeSH PA D000922 Immunotoxins
MeSH PA D009676 Noxae
MeSH PA D050257 Tubulin Modulators

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
HER2-positive carcinoma of breast indication 427685000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Receptor tyrosine-protein kinase erbB-2 Kinase ANTIBODY BINDING DRUG LABEL DRUG LABEL
Tubulin beta Tumour-associated antigen INHIBITOR DRUG LABEL DRUG LABEL

External reference:

IDSource
SE2KH7T06F UNII
D09980 KEGG_DRUG
4032192 VUID
N0000186780 NUI
4032192 VANDF
C2935436 UMLSCUI
CHEMBL1743082 ChEMBL_ID
DB05773 DRUGBANK_ID
CHEMBL1201585 ChEMBL_ID
CHEMBL2109399 ChEMBL_ID
9295 INN_ID
6928 IUPHAR_LIGAND_ID
1371041 RXNORM
199194 MMSL
29308 MMSL
d08069 MMSL
014910 NDDF
702836004 SNOMEDCT_US
896752005 SNOMEDCT_US
D000080044 MESH_DESCRIPTOR_UI
CHEMBL2109484 ChEMBL_ID
168318470 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
KADCYLA HUMAN PRESCRIPTION DRUG LABEL 1 50242-087 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS BLA 32 sections
KADCYLA HUMAN PRESCRIPTION DRUG LABEL 1 50242-087 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS BLA 32 sections
KADCYLA HUMAN PRESCRIPTION DRUG LABEL 1 50242-087 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS BLA 32 sections
KADCYLA HUMAN PRESCRIPTION DRUG LABEL 1 50242-088 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS BLA 32 sections
KADCYLA HUMAN PRESCRIPTION DRUG LABEL 1 50242-088 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS BLA 32 sections
KADCYLA HUMAN PRESCRIPTION DRUG LABEL 1 50242-088 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS BLA 32 sections